Sechenov University Will Test A Drug For The Treatment Of Severe COVID-19

Table of contents:

Sechenov University Will Test A Drug For The Treatment Of Severe COVID-19
Sechenov University Will Test A Drug For The Treatment Of Severe COVID-19

Video: Sechenov University Will Test A Drug For The Treatment Of Severe COVID-19

Отличия серверных жестких дисков от десктопных
Video: I.M. Sechenov First Moscow State Medical University | MBBS In Russia | Education Abroad 2023, February
Anonim

Sechenov University will test a drug for the treatment of severe COVID-19

The Russian biotechnological drug artelegia (olokizumab) is included in the guidelines of the Ministry of Health for the prevention, diagnosis and treatment of coronavirus.

Sechenov University will test a drug for the treatment of severe COVID-19
Sechenov University will test a drug for the treatment of severe COVID-19

Pharmaceutical complex for the production of finished dosage forms and biotechnological substances R-PHARM in Yaroslavl / Photo: gmpnews.ru

According to the press service of the Sechenov University, the drug was developed by the R-Pharm. Artlegia (olokizumab) is an antibody that directly blocks the inflammatory mediator Interleukin-6 (IL-6). With moderate to severe and progressive COVID-19, the body maximally activates the defense mechanisms of the immune system to fight the virus, which causes an uncontrolled release of inflammatory mediator proteins, in particular IL-6. This leads to a cytokine storm - a potentially lethal response by the immune system to the virus - and damage to the lungs, heart, and kidneys. The mechanism of action of the drug affects proteins and reduces the body's immune response.

“Sechenov University was included in the clinical phase of the study of the drug olokizumab (artlegia) in patients with COVID-19 with clinical and laboratory characteristics confirming the presence of cytokine release syndrome. The study is double-blind, randomized, placebo-controlled, carried out according to international standards,”- said in the message.

The study is led by the Department of Clinical Research. The tests are being carried out in the university clinical hospitals No. 3 and 4, as well as in 17 hospitals and research institutions in Moscow, St. Petersburg, Yaroslavl, Nizhny Novgorod.

Popular by topic